1887
Rapid communication Open Access
Like 0

Abstract

Europe has experienced a large COVID-19 wave caused by the Delta variant in winter 2021/22. Using mathematical models applied to Metropolitan France, we find that boosters administered to ≥ 65, ≥ 50 or ≥ 18 year-olds may reduce the hospitalisation peak by 25%, 36% and 43% respectively, with a delay of 5 months between second and third dose. A 10% reduction in transmission rates might further reduce it by 41%, indicating that even small increases in protective behaviours may be critical to mitigate the wave.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.1.2101125
2022-01-06
2024-12-30
/content/10.2807/1560-7917.ES.2022.27.1.2101125
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/1/eurosurv-27-1-3.html?itemId=/content/10.2807/1560-7917.ES.2022.27.1.2101125&mimeType=html&fmt=ahah

References

  1. Bosetti P, Tran Kiem C, Andronico A, Colizza V, Yazdanpanah Y, Fontanet A, et al. Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France. Paris: Institut Pasteur; 2021. Available from: https://hal-pasteur.archives-ouvertes.fr/pasteur-03272638v2
  2. Béraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, et al. The French connection: the first large population-based contact survey in France relevant for the spread of infectious diseases. PLoS One. 2015;10(7):e0133203.  https://doi.org/10.1371/journal.pone.0133203  PMID: 26176549 
  3. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143-56.  https://doi.org/10.1001/jamapediatrics.2020.4573  PMID: 32975552 
  4. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM, CMMID COVID-19 working group. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205-11.  https://doi.org/10.1038/s41591-020-0962-9  PMID: 32546824 
  5. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407-16.  https://doi.org/10.1016/S0140-6736(21)02183-8  PMID: 34619098 
  6. Collin A, Hejblum BP, Vignals C, Lehot L, Thiébaut R, Moireau R, et al. Using population based Kalman estimator to model COVID-19 epidemic in France: estimating the effects of non-pharmaceutical interventions on the dynamics of epidemic. medRxiv. 2021.07.09.21260259. preprint.  https://doi.org/10.1101/2021.07.09.21260259  https://doi.org/10.1101/2021.07.09.21260259 
  7. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. , COVID-19 Genomics UK (COG-UK) consortium. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35-42.  https://doi.org/10.1016/S1473-3099(21)00475-8  PMID: 34461056 
  8. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, et al. , Danish Covid-19 Genome Consortium. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021;21(11):1507-17.  https://doi.org/10.1016/S1473-3099(21)00290-5  PMID: 34171231 
  9. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-400.  https://doi.org/10.1056/NEJMoa2114255  PMID: 34525275 
  10. Tran Kiem C, Bosetti P, Paireau J, Crépey P, Salje H, Lefrancq N, et al. SARS-CoV-2 transmission across age groups in France and implications for control. Nat Commun. 2021;12(1):6895.  https://doi.org/10.1038/s41467-021-27163-1  PMID: 34824245 
  11. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. bioRxiv. 2021.11.11.21266068. preprint.  https://doi.org/10.1101/2021.11.11.21266068  https://doi.org/10.1101/2021.11.11.21266068 
/content/10.2807/1560-7917.ES.2022.27.1.2101125
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error